| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_344b14753c7837c5be58a6b6c4470ddd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56977
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2009-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5f39b6ff94e65f1f319e7c4bf6d63f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eed0682c4fc41d107f65c2f7fd515d7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf7f3a9c93eece4b8373e7187896e3db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7dc1ca0dfb3a12664139e05d65a99f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_126264dacdd75fbe25fac0a4f692ae8a |
| publicationDate |
2009-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009226471-A1 |
| titleOfInvention |
Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment |
| abstract |
The present invention provides of using multimeric MHC class II/peptide complexes. In one aspect, methods provided for identifying MHC class II-restricted immune epitopes of a predetermined polypeptide antigen. Methods for identifying an immunostimulatory epitope for a predetermined polypeptide antigen are provided. In a related aspect, methods for screening a therapeutic polypeptide agent for an MHC class II epitope are provided. In other aspects, methods for modulating T cells and for determining or monitoring an MHC class II-restricted immune status of a patient are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011106645-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10370718-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9964540-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9733247-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9464120-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8835603-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10449228-B2 |
| priorityDate |
2001-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |